Phase II Study of Cadonilimab with S-1 or Capecitabine as Second-Line Treatment for Adults with Advanced Pancreatic Cancer

What this Trial Is About

Researchers are evaluating the effectiveness and safety of Cadonilimab combined with either S-1 or capecitabine as a second-line treatment for people with advanced pancreatic cancer. This phase II clinical trial focuses on patients who have already received standard first-line treatments and now need further therapy. The study aims to understand how well this combination works and how safe it is for these patients. Participants will receive Cadonilimab intravenously at a dose of 6 mgkg on day 1 every three weeks. Alongside this, they will take either S-1 orally twice daily at 40-60 mg from day 1 to day 14 every three weeks or capecitabine orally twice daily at 1250 mgm2 from day 1 to day 14 every three weeks. The choice between S-1 or capecitabine depends on what the patient used in their first-line treatment or the investigators decision. Treatment continues until the disease progresses or unacceptable side effects occur. During the trial, participants will be monitored closely with assessments to measure tumor response, overall survival, progression-free survival, disease control rate, and duration of response for up to two years. Researchers will also evaluate safety throughout the study. Participants can expect regular visits for evaluations, tests, and monitoring until the study ends or their condition changes.

Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer